AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24576886 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial therapy only (Control group)
Number of subjects: 40
Study 22556101 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation of bedside alcohol hand rub and materials promoting hand hygiene, with regular hand hygiene audits, rolled out nationally from 1 December 2004.
Number of subjects: 187
Study 22556101 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased procurement of soap
Number of subjects: 187
Study 22556101 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased procurement of alcohol hand rub
Number of subjects: 187
Study 22556101 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication of the Health Act 2006
Number of subjects: 187
Study 22556101 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust visits by Department of Health improvement teams
Number of subjects: 187
Study 20349405 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.7 g for three months)
Number of subjects: 206
Study 20349405 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 206
Study 18751997 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DW (n = 25) - participated in 90‐min group training twice a week for 12 weeks
Number of subjects: 77
Study 18751997 — intervention group
Group type: EXPERIMENTAL
Intervention: 1DW (n = 29) - participated in 90‐min group training once a week for 12 weeks
Number of subjects: 77
Study 18751997 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (n = 23) - no training
Number of subjects: 77
Study 11413076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban (an intravenous GP IIb/IIIa antagonist)
Number of subjects: 1160
Study 11413076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 11413076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban
Number of subjects: 1160
Study 9786314 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) administered by prolonged infusion
Number of subjects: 0
Study 9786314 — intervention group
Group type: EXPERIMENTAL
Intervention: New topoisomerase I inhibitor irinotecan
Number of subjects: 0
Study 9786314 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional treatments (resection of hepatic metastases)
Number of subjects: 0
Study 9786314 — intervention group
Group type: EXPERIMENTAL
Intervention: Different chemotherapy regimens (including nitrosoureas, mitomycin C, or cisplatin)
Number of subjects: 0
Study 7841265 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone prompts (telephone call in anticipation of a mailed questionnaire)
Number of subjects: 100
Study 7841265 — intervention group
Group type: COMPARATOR
Intervention: Conventional mailing (mailed questionnaires and reminder letter)
Number of subjects: 100
Study 3282482 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 50
Study 3282482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31209171 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training, 2 hours per week for 5 school years
Number of subjects: 144
Study 31209171 — intervention group
Group type: COMPARATOR
Intervention: Control group activities (conventional calculation and reading)
Number of subjects: 144
Study 31209171 — intervention group
Group type: EXPERIMENTAL
Intervention: AMC training
Number of subjects: 144
Study 28653108 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-containing ointment applied topically for 16 weeks, starting 3 days prior to chemotherapy.
Number of subjects: 32
Study 28653108 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied topically for 16 weeks, starting 3 days prior to chemotherapy.
Number of subjects: 32
Study 28653108 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-containing ointment
Number of subjects: 32
Study 25382593 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party intentions influencing judgments of blame
Number of subjects: 0
Study 25382593 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party intentions influencing moral judgments
Number of subjects: 0
Study 25382593 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in causal perception due to third-party intentions
Number of subjects: 0
Study 25382593 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of blame and perceived differences in situational constraint
Number of subjects: 0
Study 23460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin
Number of subjects: 142
Study 23460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant
Number of subjects: 142
Study 23460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin & antioxidant
Number of subjects: 142
Study 23460815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 21569300 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving therapy, postcards, patient support, cultural assessment, improved access to primary care, risk management strategy
Number of subjects: 0
Study 21569300 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 19755656 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 156
Study 19755656 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 156
Study 16531621 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (10 microg/kg of body weight) for 6 days
Number of subjects: 78
Study 16531621 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 days
Number of subjects: 78
Study 14641514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 25
Study 14641514 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 25
Study 14641514 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 25
Study 10831942 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent/Emergent Surgery
Number of subjects: 1100
Study 10831942 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective Surgery
Number of subjects: 1100
Study 10831942 — intervention group
Group type: COMPARATOR
Intervention: No Surgery
Number of subjects: 1100
Study 10831942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Surgery (overall)
Number of subjects: 1100
Study 9084611 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisting torque of 8‐15 Nm
Number of subjects: 6
Study 9084611 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposing torque of 8‐15 Nm
Number of subjects: 6
Study 9084611 — intervention group
Group type: COMPARATOR
Intervention: Control trials (no perturbation)
Number of subjects: 6
Study 8458913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486)
Number of subjects: 0
Study 8458913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29633621 — intervention group
Group type: EXPERIMENTAL
Intervention: OMEGA-3 PUFA-enriched eggs (3 eggs daily, 259 mg omega-3 PUFAs/egg for 3 weeks)
Number of subjects: 36
Study 29633621 — intervention group
Group type: COMPARATOR
Intervention: Ordinary hen eggs (3 eggs daily, 277 mg omega-3 PUFAs/day for 3 weeks)
Number of subjects: 36
Study 28767068 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing relevant health warnings
Number of subjects: 4072
Study 28767068 — intervention group
Group type: COMPARATOR
Intervention: Viewing other warnings
Number of subjects: 4072
Study 28767068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warnings
Number of subjects: 4072
Study 28767068 — intervention group
Group type: COMPARATOR
Intervention: General, text-only warnings (in Korea)
Number of subjects: 4072
Study 28767068 — intervention group
Group type: COMPARATOR
Intervention: Detailed pictorial warnings (in Mumbai)
Number of subjects: 4072
Study 24390764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (30 mg intravenously twice a day for 14 days)
Number of subjects: 250
Study 24390764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil
Number of subjects: 250
Study 24390764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 23718078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-air carbonate baths
Number of subjects: 0
Study 23718078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme inhalation
Number of subjects: 0
Study 23718078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined application of gas-air carbonate baths and lysozyme inhalation
Number of subjects: 0
Study 21430703 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% LDE225 cream
Number of subjects: 8
Study 21430703 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study 18829872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute and maintenance interpersonal and social rhythm therapy
Number of subjects: 0
Study 18829872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute interpersonal and social rhythm therapy and maintenance intensive clinical management
Number of subjects: 0
Study 18829872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intensive clinical management and maintenance interpersonal and social rhythm therapy
Number of subjects: 0
Study 18829872 — intervention group
Group type: COMPARATOR
Intervention: Intensive clinical management
Number of subjects: 0
Study 16764746 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide/thiotepa/carboplatin
Number of subjects: 29
Study 16764746 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose cyclophosphamide/epirubicin/5-fluorouracil
Number of subjects: 29
Study 16764746 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with chemotherapy)
Number of subjects: 29
Study 12763216 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 200 mg/m(2)/day, administered orally for 5 consecutive days of a 28-day cycle, continued for up to six cycles.
Number of subjects: 25
Study 12763216 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (patients with BM)
Number of subjects: 25
Study 12763216 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (patients without BM)
Number of subjects: 25
Study 11141365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen suspension (7 mg/kg)
Number of subjects: 103
Study 11141365 — intervention group
Group type: COMPARATOR
Intervention: Effervescent granules (200 mg for 25-40 kg; 400 mg for 35-40 kg; 400 mg for >40 kg)
Number of subjects: 103
Study 9296729 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cardiological rehabilitation programme
Number of subjects: 155
Study 9296729 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 155
Study 8409079 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods (group A)
Number of subjects: 406
Study 8409079 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 406
Study 3012991 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g soy polysaccharide
Number of subjects: 16
Study 3012991 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g soy polysaccharide
Number of subjects: 16
Study 3012991 — intervention group
Group type: COMPARATOR
Intervention: 0 g soy polysaccharide
Number of subjects: 16
Study 3012991 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g (heat processed) soy polysaccharide
Number of subjects: 16
Study 30945092 — intervention group
Group type: EXPERIMENTAL
Intervention: Special education services under the Autism classification
Number of subjects: 89
Study 30945092 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-inclusion settings
Number of subjects: 89
Study 30945092 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 89
Study 30945092 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 89
Study 30945092 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior plans
Number of subjects: 89
Study 30945092 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills instruction
Number of subjects: 89
Study 30344873 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 1 hour daily over 7 days
Number of subjects: 100
Study 30344873 — intervention group
Group type: COMPARATOR
Intervention: Routine care in the incubator
Number of subjects: 100
Study 26919044 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational engagement (M+)
Number of subjects: 68
Study 26919044 — intervention group
Group type: COMPARATOR
Intervention: Standard care (M-)
Number of subjects: 68
Study 25422824 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6‐mm long implants
Number of subjects: 60
Study 25422824 — intervention group
Group type: COMPARATOR
Intervention: 9.6 mm or longer implants
Number of subjects: 60
Study 22634246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with different loadings of synthetic and natural l-menthol (1 and 4mg ISO tar yields)
Number of subjects: 200
Study 22634246 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes with no menthol
Number of subjects: 200
Study 19954383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP) in HIV-positive mothers
Number of subjects: 302
Study 19954383 — intervention group
Group type: COMPARATOR
Intervention: Placebo in HIV-positive mothers
Number of subjects: 302
Study 19954383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP) in HIV-negative mothers
Number of subjects: 302
Study 19954383 — intervention group
Group type: COMPARATOR
Intervention: Placebo in HIV-negative mothers
Number of subjects: 302
Study 19954383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP)
Number of subjects: 302
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: ABQ method for diagnosing vertebral fractures
Number of subjects: 732
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ method for diagnosing vertebral fractures
Number of subjects: 732
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: QM-triage method for diagnosing vertebral fractures
Number of subjects: 732
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: ABQ method for diagnosing short vertebral height
Number of subjects: 732
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of BMD in men with VF vs. without VF
Number of subjects: 732
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of BMD in men with SVH vs. normal vertebrae
Number of subjects: 732
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of BMD in men with VF identified by all three methods
Number of subjects: 732
Study 17563237 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of BMD in men identified by a single method
Number of subjects: 732
Study 15711503 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen and 20% nitrogen during anesthesia and 80% oxygen in recovery
Number of subjects: 38
Study 15711503 — intervention group
Group type: COMPARATOR
Intervention: 70% nitrous oxide and 30% oxygen during anesthesia, followed by 30% oxygen in recovery
Number of subjects: 38
Study 12502651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg t.i.d. for 4 weeks)
Number of subjects: 18
Study 10098585 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural + general anesthesia + Aprotinin
Number of subjects: 60
Study 10098585 — intervention group
Group type: COMPARATOR
Intervention: Epidural + general anesthesia + placebo
Number of subjects: 60
Study 10098585 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia + Aprotinin
Number of subjects: 60
Study 10098585 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia + placebo
Number of subjects: 60
Study 8678393 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy for chronic hepatitis C infection (mean duration 19.5 months)
Number of subjects: 35
Study 8678393 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (mean follow-up 28 months)
Number of subjects: 35
Study 1880224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 24
Study 1880224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 24
Study 1880224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (general)
Number of subjects: 24
Study 1880224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-hydroxyalprazolam
Number of subjects: 24
Study 7105818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor, 150 mg 3-times daily
Number of subjects: 87
Study 7105818 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin, 150 mg 3-times daily
Number of subjects: 87
Study 7105818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (hospital-acquired infection)
Number of subjects: 87
Study 7105818 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (hospital-acquired infection)
Number of subjects: 87
Study 31233662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain diary
Number of subjects: 389
Study 31233662 — intervention group
Group type: COMPARATOR
Intervention: Comfort diary
Number of subjects: 389
Study 28827788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (VD group, n=29)
Number of subjects: 54
Study 28827788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group, n=29)
Number of subjects: 54
Study 28586586 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpatellar tendon approach
Number of subjects: 60
Study 28586586 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar tendon approach
Number of subjects: 60
Study 24589242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain (4 × 250 mg)
Number of subjects: 45
Study 24589242 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (4 × 25 mg)
Number of subjects: 45
Study 24589242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22070512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole (10 mg/d)
Number of subjects: 494
Study 22070512 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg/d)
Number of subjects: 494
Study 20667792 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 19
Study 20667792 — intervention group
Group type: EXPERIMENTAL
Intervention: Other time-dependent measures of HRV (SDNN, SDANN)
Number of subjects: 19
Study 17604453 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype frequencies of ten autosomal minor H antigens
Number of subjects: 2685
Study 16097050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume CVVH
Number of subjects: 37
Study 16097050 — intervention group
Group type: COMPARATOR
Intervention: Low-volume CVVH
Number of subjects: 37
Study 16097050 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CVVH
Number of subjects: 37
Study 16097050 — intervention group
Group type: COMPARATOR
Intervention: Late CVVH
Number of subjects: 37
Study 16097050 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival patients
Number of subjects: 37
Study 12200812 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of recombinant human EPO (rHuEPO) in groups A and C1
Number of subjects: 47
Study 12200812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membranes (CL-Es) in group C
Number of subjects: 47
Study 12200812 — intervention group
Group type: COMPARATOR
Intervention: Low doses of rHuEPO in groups B and C2
Number of subjects: 47
Study 10029961 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine
Number of subjects: 31
Study 10029961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (commercial instant tea and deionized water)
Number of subjects: 31
Study 8559499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (6 g/day) for 12 weeks
Number of subjects: 12
Study 8559499 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) (3 mg/kg)
Number of subjects: 12
Study 8559499 — intervention group
Group type: COMPARATOR
Intervention: Control study without CsA intake
Number of subjects: 12
Study 1988894 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 108
Study 6182469 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch-blocker tablets
Number of subjects: 0
Study 6182469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31587103 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer-coated everolimus-eluting stents (BP-EES)
Number of subjects: 13
Study 31587103 — intervention group
Group type: COMPARATOR
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 13
Study 31646767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 10 mg/kg intravenous dose of methylprednisolone
Number of subjects: 64
Study 31646767 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher (30 mg/kg) or more frequent (twice) dosing of methylprednisolone
Number of subjects: 64
Study 31646767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27716660 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 84
Study 27716660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 26394225 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed Endurance Production (SEP) training
Number of subjects: 13
Study 26394225 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed Endurance Maintenance (SEM) training
Number of subjects: 13
Study 22392970 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil of ginger
Number of subjects: 301
Study 22392970 — intervention group
Group type: EXPERIMENTAL
Intervention: Blend of essential oils (ginger, spearmint, peppermint, cardamom)
Number of subjects: 301
Study 22392970 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol
Number of subjects: 301
Study 22392970 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 301
Study 21334898 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased ankle pushoff instructions
Number of subjects: 24
Study 21334898 — intervention group
Group type: COMPARATOR
Intervention: Increased ankle pushoff instructions
Number of subjects: 24